Holen Sie sich die Stockscreener-App
103.63
1.75%
1.78
Handel nachbörslich:
103.58
-0.05
-0.05%
Schlusskurs vom Vortag:
$101.85
Offen:
$101.21
24-Stunden-Volumen:
559.30K
Relative Volume:
0.46
Marktkapitalisierung:
$9.14B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-168.74M
KGV:
-43.95
EPS:
-2.3577
Netto-Cashflow:
$-185.87M
1W Leistung:
-1.22%
1M Leistung:
+4.73%
6M Leistung:
+182.91%
1J Leistung:
+514.65%
1-Tages-Spanne:
$95.61
$104.13
1-Wochen-Bereich:
$95.61
$107.00
52-Wochen-Spanne:
$14.51
$108.14
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
103.63 | 9.18B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Wall Street Zen Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Sell - marketbeat.com
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123 - moomoo.com
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Perceptive Advisors discloses 4.9% stake in Spyre Therapeutics (SYRE) via Master Fund - Stock Titan
RTW Investments (SYRE) reports 4.8% Spyre Therapeutics stake for managed funds - Stock Titan
Dimensional Fund Advisors LP Sells 29,593 Shares of Spyre Therapeutics, Inc. $SYRE - marketbeat.com
Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $126.85, Implies 22% Upside - TradingView
Price to earnings forward of Spyre Therapeutics, Inc – SWB:3920 - TradingView
Price to book forward of Spyre Therapeutics, Inc – SWB:3920 - TradingView
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, BTIG Research Analyst Says - marketbeat.com
SYRE Maintained by BTIG -- Price Target Raised to $132.00 - GuruFocus
Spyre Therapeutics director Jeffrey W. Albers disposes of USD 2.39 million in common shares - Bitget
Spyre Therapeutics, Inc. $SYRE Shares Bought by Bank of America Corp DE - marketbeat.com
Spyre Therapeutics Insider Sold Shares Worth $2,404,190, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics director Albers sells $2.4m in stock By Investing.com - Investing.com India
Spyre Therapeutics director Albers sells $2.4m in stock - Investing.com India
Spyre Therapeutics (NASDAQ:SYRE) Director Sells 18,000 Shares - marketbeat.com
Spyre Therapeutics (SYRE) director logs 5,000-share option exercise and 23,000-share sale - Stock Titan
Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa - marketscreener.com
Spyre Therapeutics Announces Launch Of Spy772 Program - TradingView
Spyre Therapeutics launches combination therapy trial for hidradenitis suppurativa - Investing.com
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa - The Manila Times
Spyre Therapeutics launches combination therapy trial for hidradenitis suppurativa By Investing.com - Investing.com Canada
Spyre Therapeutics, Inc. Launches SPY772 Program And Initiates Phase 2 SKYLIGHT Trial In Hidradenitis Suppurativa - marketscreener.com
California State Teachers Retirement System Purchases 11,204 Shares of Spyre Therapeutics, Inc. $SYRE - marketbeat.com
Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data? - Yahoo Finance
Price to sales forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128 - Moomoo
Spyre Therapeutics (NASDAQ:SYRE) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
Spyre Therapeutics, Inc. SEC Filing (Aug 7, 2026) - Stock Titan
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics, Inc. (SYRE) Investor Outlook: Promising Biotech with 4.98% Upside Potential - DirectorsTalk Interviews
Price to earnings forward of Spyre Therapeutics, Inc – DUS:3920 - TradingView
Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know - The Motley Fool
A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know - The Motley Fool
SPYRE THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $121 FROM $88 - webull.com
We Think Spyre Therapeutics (NASDAQ:SYRE) Can Easily Afford To Drive Business Growth - moomoo.com
Cameron Turtle, Spyre Therapeutics CEO, sells $1.43m in stock By Investing.com - Investing.com South Africa
Spyre CFO Scott Burrows sells $716,771 in stock By Investing.com - Investing.com Nigeria
Form 4 Spyre Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Cameron Turtle, Spyre Therapeutics CEO, sells $1.43m in stock - Investing.com
A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $112 to $130 - Moomoo
The Manufacturers Life Insurance Company Trims Stock Position in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Insider Sold Shares Worth $1,432,705, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics (SYRE) CEO Cameron Turtle Sells 15,000 Shares - GuruFocus
SPYRE THERAPEUTICS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $124 FROM $106 - webull.com
Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $130 - moomoo.com
SPYRE THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $115 FROM $90 - webull.com
Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $1,432,650.00 in Stock - marketbeat.com
Spyre Therapeutics (SYRE) CEO trades 15,000 shares under 10b5-1 plan - Stock Titan
Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.43, Implies 14% Upside - TradingView
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):